

Publications core members 2020-2021

Lussier F, Pascoal TA, Chamoun M, Therriault J, Tissot C, Sabard M, Kang MS, Mathotaarachchi SS, Benedet AL, Thomas EM, Parsons M, **Ismail Z, Rosa-Neto P, Gauthier S**. Mild Behavioral impairment is associated with β -amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. *Alzheimer's & Dementia*. 2020; 16: 192-199. DOI: 10.1002/alz.12007. Impact Factor 17.1

Ng KP, Therriault J, Kang MS, Struyfs H, Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, **Massarweh G**, Soucy JP, **Rosa-Neto P, Gauthier S**. Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy. *Neuroimage: Clinical*. 2019;24,102091. DOI: 10.1016/j.nicl.2019.102091. Impact Factor 3.9

Wang H, Li T, **Gauthier S**, Yu E, Tang Y, Barbarino P, Yu X. Coronavirus epidemic and geriatric mental healthcare in China: how a coordinated response by professional organizations helped older adults during an unprecedented crisis. *International Psychogeriatrics*. 2020; 1-4. DOI:1.1017/S1041610220000551. PMID: 32240625. Impact Factor 2.9

Wang H, Li T, Barbarino P, **Gauthier S**, Brodaty H, Molinuevo JL, Xie Y, Sun Y, Yu E, Tang Y, Weidner W, Yu X. Dementia care during COVID-19. *Lancet*. 2020;395 (10231): 1190-1. DOI: 10.1016/S0140-6736(20)30755-8. PMID: 32240625. Impact Factor 59.1

Yu JT, Xu W, Tan CC, Andrieu S, Suckling J, Evangelou E, Pan A, Zhang C, Jia J, Feng L, Kua EH, Wang YJ, Wang HF, Tan MS, Li JQ, Hou XH, Wan Y, Tan L, Mok V, Tan L, Dong Q, Touchon J, **Gauthier S**, Aisen PS, Vellas B. Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 423 observational prospective studies and 153 randomized controlled trials. *Journal of Neurology, Neurosurgery and Psychiatry*, DOI: 10.1136/jnnp-2019-321913. Impact Factor 8.2

Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, Chamoun M, Tissot C, Lussier F, Mohaddes S, Soucy JP, **Massarweh G, Gauthier S, Rosa-Neto P**. for the Alzheimer's Disease Neuroimaging Initiative. Topographical distribution of A β predicts progression to dementia in A β positive mild cognitive impairment. *Alzheimer's & Dementia - DADM*, 2020;12(1):e12037. DOI:10.1002/dad2.12037. PMID: 32582834. Impact Factor 17.1

Shields H, Schelter BO, bentham P, Baddeley TC, Baddeley TC, Rubino CM, Ganesan H, Hammel G, Vuksanovic V, Staff RT, Murray AD, Bracoud L, Wischik DM, Riedel G, **Gauthier S**, Jia JP, Moebius HJ, Hardlund J, Kipps CM, Kook K, Storey JMD, Harrington CR, Wischik C. Concentration-dependant activity of hydromethylthionine on clinical decline and brain atrophy in a randomized controlled trial in behavioural variant fronto-temporal dementia. *Journal of Alzheimer Disease*, 75, 501-519, 2020. DOI:10.3233/JAD-191173. PMID: 7306898. Impact Factor 3.9

Karikari T, Pascoal TA, Ashton N, Janelidze S, Benedet AL, Rodriguez J, Chamoun M, Savard M, Kang P, Therriault J, Schöll M, **Massarweh G**, Soucy JP, Höglund K, Brinkman G, Mattson N, Palmquist S, **Gauthier S**, Stomrud E, Zetterberg H, Hansson O, **Rosa-Neto P**, Blennow K. Blood phosphorylated tau181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective studies. *Lancet Neurology*. 19, 422-433, 2020. DOI: 10.1016/S1474-4422(20)30071-5. PMID: 3233900. Impact Factor 30.9

Tremblay-Mercier J, Madjar C, Das S, Dyke SOM, Etienne P, Lafaille-Magnan ME, Bellec P, **Collins L, Rajah MN**, Bohbot VD, Leoutsakos JM, Iturria-Medina Y, Kat J, Hoge RD, **Gauthier S, Chakravarty MM**, Poline **JB, Rosa-Neto P, Villeneuve S**, Evans AC, **Poirier J, Breitner JCS** & the PREVENT-AD Research Group. Creation of an open science dataset from PREVENT-AD, a longitudinal cohort study of pre-symptomatic Alzheimer's disease. *BioRxiv*, DOI:10.1101/2020.03.04.976670.

Gauthier S, Aisen PS, Cummings J, Detke MJ, Longo FM, Raman R, Sabbagh M, Schneider L, Tanzi R, Tariot P, Weiner M, Touchon J, Vellas B, and the EU/US CTAD Task Force. Non-amyloid approaches to disease modification for Alzheimer's disease: an EU/US Task Force report. *Journal of Prevention of Alzheimer's Disease*. 2020; 1-6. DOI: 10.14283/jpad.2020.18. PMID: 32420298. ****

Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, Tissot C, Qureshi MNI, Kang MS, Mathotaarachchi S, Stevenson J, Hopewell R, **Massarweh G**, Soucy JP, **Gauthier S, Rosa-Neto P**. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. *Brain*, DOI:10.1093/brain/awaa180. PMID: 32671408. Impact Factor 11.3

Ismail Z, Black SE, Camcioli R, **Chertkow H**, Herrmann N, Laforce R, Odasso MM, Rockwood K, **Rosa-Neto P**, Seitz D, Sivanathan S, Smith EE, Soucy JP, Vedel I, **Gauthier S** on behalf of the CCCDTD5 participants. Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. *Alzheimer's & Dementia*. 2020; 16: 1182-1195. DOI:10.1002/alz.12105. Impact Factor 17.1

Therriault J, Benedet A, Pascoal T, Mathotaarachchi S, Savard M, Chamoun M, Thomas E, Kang MS, Lussier F, Tissot C, Soucy JP, **Massarweh G, Saha-Chaudhuri P, Poirier J, Gauthier S, Rosa-Neto P**. APOE ϵ 4 potentiates the relationship between amyloid- β and tau pathologies. *Molecular Psychiatry*. DOI: 10.1038/s41380-020-0688-6. PMID: 32161362. Impact Factor 12.3

Therriault J, Benedet A, Pascoal TA, Savard M, Ashton NL, Chamoun M, Tissot C, Lussier F, Kang NS, Berzgin G, Wang T, Fernandes-Arias J, **Massarweh G, Vitali P**, Zetterberg H, Blennow K, **Saha-Chaudhuri P**, Soucy JP, **Gauthier S, Rosa-Neto P**. Determining amyloid- β positivity using [18F]AZD4694 PET imaging. *Journal of Nuclear Medicine*. DOI: 10.2967/jnumed.120.245209. Impact Factor 7.3

Wang HF, Shen XN, Li JQ, Suckling J, Tan CC, Wang YJ, Feng L, Zhang C, Tan L, Dong Q, Touchon J, **Gauthier S**, Yu JT, ADNI. Clinical and biomarker trajectories in sporadic Alzheimer's disease: a longitudinal study. *Alzheimer's & Dementia – DADM*. DOI: 10.1002/dad2.12095. Impact Factor 17.1

Gauthier S, Chertkow H, Therriault J, Chayer C, Ménard MC, Lacombe G, **Rosa-Neto, P, Ismail Z**. CCCDTD5: research diagnostic criteria for Alzheimer's disease. *Alzheimer's & Dementia – TRCI*. DOI: 10.1002/trc2.12036. Impact Factor 17.1

Smith EE, Couillard P, Fisk JD, **Ismail Z**, Montero-Odasso M, Robillard J, Vedel I, Sivananthan S, **Gauthier S**. Pandemic dementia scarce resource allocation. *Canadian Geriatrics Journal*, 23 (3); 216-218, Sept 2020. Impact Factor 0.75

Kang MS, Aliaga A, Shin M, Mathotaarachchi S, Benedet AL, Pascoal TA, Therriault J, Chamoun M, Savard M, Devenyi GA, Mathieu A, **Chakravarty MM**, Sandelius A, Blennow K, Zetterberg H, Soucy JP, **Cuello AC, Massarweh G, Gauthier S, Rosa-Neto P** for the Alzheimer Disease Neuroimaging Initiative. Amyloid modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. *Molecular Psychiatry*. DOI: 10.1038/s41380-020-0818-1. PMID: 32591633. Impact Factor 12.3

Smith EE, Barber P, Field T, Ganesh A, Hachinski V, Hogan DB, Lanctot K, Lindsay P, Sahlas D, Sharma M, Swartz R, **Ismail Z, Gauthier S**, Black SE. CCCDTD5: Guidelines for management of Vascular Cognitive Impairment. *Alzheimer's & Dementia – TRCI*. DOI: 10.1002/trc2.12056. Impact Factor 17.1

Paquin V, Therriault J, Pascoal TA, **Rosa-Neto P, Gauthier S**. Frontal variant of Alzheimer's disease differentiated from frontotemporal dementia using in vivo tau and amyloid imaging. *Cognitive and Behavioral Neurology*, 33, 288-203, 2020. Impact Factor 1.4

Kwan ATH, Arfae S, Therriault J, **Rosa-Neto P, Gauthier S**. Lessons learned from the second generation of anti-amyloid monoclonal antibodies clinical trials. *Dementia Geriatric Cognitive Disorders* DOI:10.1159/000511506. ****

Geddes MR, O'Connell ME, Fisk JD, **Gauthier S**, Camicioli R, **Ismail Z**, for the Alzheimer Society of Canada Task Force on Dementia Care Best Practice for COVID-19. Remote cognitive and behavioural assessments: report of the Alzheimer Society of Canada Task Force on Dementia Care Best Practice for COVID-19. *Alzheimer's & Dementia – DADM*. DOI: 10.1002/dad2.12111. Impact Factor 17.1

Bateman D, Gill S, Hu S, Foster E, Ruthirakuhan M, Sellek A, Mortby M, Matuskova V, **Ng KP**, Freund-Levi Y, Kumar S, Tarawneh R, **Gauthier S**, Rosenberg P, de Oliveira FF, Devanand D, Ballard C, **Ismail Z**, for the NPS Professional Interest Area of the ISTAART. Agitation and impulsivity in mid and late life as possible risk for incident dementia. *Alzheimer's & Dementia-TRCI*. 2020;6(e)12016; DOI 10.002/trc2.12016. Impact Factor 17.1

Ng KP, Chiew HJ, Hameed S, Ting SKS, Ng A, Coo SA, Wong B, Lim L, Yong ACW, Mok VCT, **Rosa-Neto P**, Dominguez J, Kim SY, Hsiung GYR, Ikeba M, Miller BL, **Gauthier S**, Kandiah N. Frontotemporal dementia and COVID-19: hypothesis generation and roadmap for future research. *Alzheimer's & Dementia-TRCI*. 2020;6(e)12085; DOI 10.1002/trc2.12085. Impact Factor 17.1

Kwan A, Arfae S, Therriault J, **Rosa-Neto P, Gauthier S**. Lessons learnt from the second generation of anti-amyloid monoclonal antibodies clinical trials. *Dementia and Geriatric Cognitive Disorders*. DOI 10.1159/000511506. *****

Benedet AL, Leuzy A, Pascoal TA, Ashton NJ, Mathotaarachchi S, Savard M, Therriault J, Kang MS, Chamoun M, Schöll M, **Zimmer ER, Gauthier S**, Labbe A, Zetterberg H, **Rosa-Neto P**, Blennow K. Stage-specific links between plasma neurofilament light and biomarkers of Alzheimer's disease. *BRAIN*, DOI:10.1093/brain/awaa342. Impact Factor 11.3

Vedel I, Sheets D, McAiney C, Clare L, Brodaty H, Mann J, Anderson N, Liu-Ambrose T, Loftus L, **Gauthier S**, Sivananthan S. CCCDTD5: Individual and community-based psychological and other non-pharmacological interventions to support persons living with dementia and their caregivers. *Alzheimer's & Dementia – TRCI*. 2020;6:e12086; DOI: 10.1002/trc2.12086. Impact Factor 17.1

Tang-Wai DF, Smith EE, Bruneau MA, Burhan AM, Chatterjee A, **Chertkow H**, Choudhury S, Dorri E, Ducharme S, Fisher CE, Ghodasara S, Herrmann N, Hsiung GYR, Kumar S, Laforce R, Lee L, Massoud F, Shulman KI, Stiffel M, **Gauthier S, Ismail Z**. CCCDTD5 recommendations on early and timely assessment of neurocognitive disorders using cognitive, behavioural, and functional scales. *Alzheimer's & Dementia – TRCI*. DOI: 10.1002/trc2.12057. Impact Factor 17.1

Gauthier S, Therriault J, Pascoal TA, **Rosa-Neto P**. Impact of p-tau181 and p-tau217 levels on enrollment for randomized clinical trials and future use of anti-amyloid and anti-tau drugs. *Expert Review of Neurotherapeutics*, 20; 1211-1213, 2020. DOI: 10.1080/14737175.2020.1841637. *****

Tam M, **Gauthier S, Ng KP**, Everett F, Robillard JM. Facilitating recruitment for dementia research: insight from an international panel. *Dementia*. DOI: 10.1177/1471301220981241. Impact Factor 3.7

Ng KP, Pascoal TA, Mathotaarachchi S, Chan YH, Jiang L, Therriault J, Benedet AL, Shin M, Kandiah N, Greenwood CMT, **Rosa-Neto P, Gauthier S** and the Dominantly Inherited Alzheimer Network. Neuropsychiatry symptoms are early indicators of an upcoming metabolic decline in Alzheimer's Disease. *Translational Neurodegeneration*. DOI:10.1186/s40035-020-00225-y, 2021. Impact Factor 5.5

Therriault J, Pascoal TA, Savard M, Benedet AL, Chamoun M, Lussier F, Tissot C, Kang MS, Kunach P, Thomas E, **Massarweh G, Vitali P**, Soucy JP, **Saha-Chaudhuri P, Gauthier S, Rosa-Neto P**. Topographic distribution of amyloid- β , Tau, and atrophy in patients with behavioural/dysexecutive Alzheimer's disease. *Neurology*. 2021; 96: e81-e82. DOI:10.1212/WNL.0000000000011081. Impact Factor 8.0

Cloutier S, **Chertkow H**, Kergoat MJ, **Gélinas I, Gauthier S**, Belleville S. Trajectories of decline on instrumental activities of daily living prior to dementia in persons with mild cognitive impairment. *International Journal of Geriatric Psychiatry*, 2021; 36 :314-323. Impact Factor 3.1

Van den Brink S, El Amrani L, Therriault J, **Gauthier S, Rosa-Neto P, Vitali P**. Diagnostic impact of cerebrospinal fluid biomarkers in atypical dementias in Canada. *Canadian Journal of Neurological Sciences*. DOI:10.1017/cjn.2020.196. Impact Factor 2.2

Therriault J, Pascoal TA, Benedet AL, Tissot C, Savard M, Chamoun M, Lussier F, Kang MS, Berzgin G, Wang T, Fernandes-Arias J, **Massarweh G**, Soucy JP, **Vitali P, Sara-Chaudhuri P, Gauthier S, Rosa-Neto P**. Frequency of biologically-defined AD in relation to age, sex, APOE ϵ 4 and cognitive impairment. *Neurology*. DOI:10.1212/WNL.0000000000011416. Impact Factor 8.0

Corriveau-Lecavalier N, Duchesne **S, Gauthier S**, Hudon C, Kergoat MJ, Mellah S, Belleville S, for the Consortium for the Early Identification of Alzheimer's Disease-Quebec (CIMA-Q). A quadratic function of activation in individuals at risk of Alzheimer's disease. *Alzheimer's & Dementia – TRCI*. 2020;12:e12139. DOI:10.1002/dad2.12139. Impact Factor 17.1

McSweeney M, Pichet Binette A, Meyer PF, Gonneaud J, Bedetti C, Ozlen H, Labonté A, **Rosa-Neto P, Breitner J, Poirier J, Villeneuve S**; PREVENT-AD Research Group. Intermediate flortaucipir uptake is associated with A β -PET and CSF tau in asymptomatic adults. *Neurology*. 2020 Mar 17;94(11):e1190-e1200. doi: 10.1212/WNL.0000000000008905. Epub 2020 Feb 3. PMID: 32015176. Impact Factor 8.09

Kang MS, Aliaga AA, Shin M, Mathotaarachchi S, Benedet AL, Pascoal TA, Therriault J, Chamoun M, Savard M, Devenyi GA, Mathieu A, **Chakravarty MM**, Sandelius Å, Blennow K, Zetterberg H, Soucy JP, **Cuello AC, Massarweh G, Gauthier S, Rosa-Neto P**; Alzheimer's Disease Neuroimaging Initiative. Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. *Mol Psychiatry*. 2020 Jun 26. doi: 10.1038/s41380-020-0818-1. Epub ahead of print. PMID: 32591633. Impact Factor 12.3

Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Chamoun M, Savard M, Thomas E, Kang MS, Lussier F, Tissot C, Parsons M, Qureshi MNI, **Vitali P, Massarweh G**, Soucy JP, Rej S, **Saha-Chaudhuri P, Gauthier S, Rosa-Neto P**. Association of Apolipoprotein E ϵ 4 With Medial Temporal Tau Independent of Amyloid- β . *JAMA Neurol*. 2020 Apr 1;77(4):470-479. doi: 10.1001/jamaneurol.2019.4421. PMID: 31860000; PMCID: PMC6990684. Impact Factor 13.6

Therriault J, Benedet AL, Pascoal TA, Savard M, Ashton NJ, Chamoun M, Tissot C, Lussier F, Kang MS, Bezgin G, Wang T, Fernandes-Arias J, **Massarweh G, Vitali P**, Zetterberg H, Blennow K, **Saha-Chaudhuri P, Soucy JP, Gauthier S, Rosa-Neto P**. Determining Amyloid- β Positivity Using 18F-AZD4694 PET Imaging. *J Nucl Med*. 2021 Feb;62(2):247-252. doi: 10.2967/jnumed.120.245209. Epub 2020 Jul 31. PMID: 32737243. Impact Factor 7.3

Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Savard M, Chamoun M, Thomas E, Kang MS, Lussier F, Tissot C, Soucy JP, **Massarweh G**, Rej S, **Saha-Chaudhuri P, Poirier J, Gauthier S, Rosa-Neto P**; Alzheimer's Disease Neuroimaging Initiative. APOE ϵ 4 potentiates the relationship between amyloid- β and tau pathologies. *Mol Psychiatry*. 2020 Mar 11. doi: 10.1038/s41380-020-0688-6. Epub ahead of print. PMID: 32161362. Impact Factor 12.3

Therriault J, Pascoal TA, Savard M, Benedet AL, Chamoun M, Tissot C, Lussier F, Kang MS, Thomas E, Terada T, Rej S, **Massarweh G**, Nasreddine Z, **Vitali P**, Soucy JP, **Saha-Chaudhuri P**, **Gauthier S**, **Rosa-Neto P**. Topographic Distribution of Amyloid- β , Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease. *Neurology*. 2021 Jan 5;96(1):e81-e92. doi: 10.1212/WNL.0000000000011081. Epub 2020 Oct 22. PMID: 33093220; PMCID: PMC7884976. Impact Factor 8.0

Therriault J, Pascoal TA, Benedet AL, Tissot C, Savard M, Chamoun M, Lussier F, Kang MS, Berzgin G, Wang T, Fernandes-Arias J, **Massarweh G**, Soucy JP, **Vitali P**, **Saha-Chaudhuri P**, **Gauthier S**, **Rosa-Neto P**. Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ϵ 4, and Cognitive Impairment. *Neurology*. 2021 Feb 16;96(7):e975-e985. doi: 10.1212/WNL.0000000000011416. Epub 2020 Dec 21. PMID: 33443136. Impact Factor 8.0

Shulman KI, Stiffel M, **Gauthier S**, **Ismail Z**. CCCDTD5 recommendations on early and timely assessment of neurocognitive disorders using cognitive, behavioral, and functional scales. *Alzheimers Dement (N Y)*. 2020 Nov 11;6(1):e12057. doi: 10.1002/trc2.12057. PMID: 33209972; PMCID: PMC7657153. Impact Factor 17.1

Cristini J, Weiss M, De Las Heras B, Medina-Rincón A, **Dagher A**, Postuma RB, Huber **R**, **Doyon J**, **Rosa-Neto P**, Carrier J, Amara AW, **Roig M**. The effects of exercise on sleep quality in persons with Parkinson's disease: A systematic review with meta-analysis. *Sleep Med Rev*. 2021 Feb;55:101384. doi: 10.1016/j.smr.2020.101384. Epub 2020 Sep 8. PMID: 32987321. Impact Factor 10.5

Brisson M, Brodeur C, Létourneau-Guillon L, Masellis M, Stoessl J, Tamm A, Zukotynski K, **Ismail Z**, **Gauthier S**, **Rosa-Neto P**, Soucy JP. CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. *Alzheimers Dement (N Y)*. 2021 Jan 22;6(1):e12098. doi: 10.1002/trc2.12098. PMID: 33532543; PMCID: PMC7821956. Impact Factor 17.1

Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, **Rosa-Neto P**, Narayanan S, El Mestikawy S, **Leyton M**, Benkelfat C. Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans. *J Psychiatry Neurosci*. 2021 Jan 4;46(1):E1-E13. doi: 10.1503/jpn.190162. PMID: 32559027. Impact Factor 5.8

Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J, Schöll M, **Massarweh G**, Soucy JP, Höglund K, Brinkmalm G, Mattsson N, Palmqvist S, **Gauthier S**, Stomrud E, Zetterberg H, Hansson O, **Rosa-Neto P**, Blennow K. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *Lancet Neurol*. 2020 May;19(5):422-433. doi: 10.1016/S1474-4422(20)30071-5. PMID: 32333900. Impact Factor 30.0

DuBois JM, Mathotaarachchi S, Rousset OG, Sziklas V, Sepulcre J, Guiot MC, Hall JA, **Massarweh G**, Soucy JP, **Rosa-Neto P**, Kobayashi E. Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia. *Neuroimage Clin*. 2021;29:102552. doi: 10.1016/j.nicl.2020.102552. Epub 2020 Dec 29. PMID: 33401137; PMCID: PMC7787952. Impact Factor 3.9

Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, Chamoun M, Tissot C, Lussier F, Mohaddes S, Soucy JP, **Massarweh G**, **Gauthier S**, **Rosa-Neto P**; Alzheimer's Disease Neuroimaging Initiative. Topographical distribution of A β predicts progression to dementia in A β positive mild cognitive impairment. *Alzheimers Dement (Amst)*. 2020 Jun 21;12(1):e12037. doi: 10.1002/dad2.12037. PMID: 32582834; PMCID: PMC7306519. Impact Factor 17.1

Bateman DR, Gill S, Hu S, Foster ED, Ruthirakuhan MT, Sellek AF, Mortby ME, Matušková V, **Ng KP**, Tarawneh RM, Freund-Levi Y, Kumar S, **Gauthier S**, Rosenberg PB, Ferreira de Oliveira F, Devanand DP, Ballard C, Ismail Z; International Society to Advance Alzheimer's Research and Treatment (ISTAART), Neuropsychiatric Syndromes Professional Interest Area (NPS-PIA). Agitation and impulsivity in mid and late life as possible risk markers for incident dementia. *Alzheimers Dement* (N Y). 2020 Sep 6;6(1):e12016. doi: 10.1002/trc2.12016. PMID: 32995467; PMCID: PMC7507499. Impact Factor 17.1

Tam MT, **Gauthier S**, **Ng KP**, Everett F, Robillard JM. Facilitating recruitment for dementia research: Insights from an international panel (innovative practice). *Dementia* (London). 2020 Dec 19;1471301220981241. doi: 10.1177/1471301220981241. Epub ahead of print. PMID: 33342280. Impact Factor 2.2

Pizzarotti B, Palesi F, **Vitali P**, Castellazzi G, Anzalone N, Alvisi E, Martinelli D, Bernini S, Cotta Ramusino M, Ceroni M, Micieli G, Sinforiani E, D'Angelo E, Costa A, Gandini Wheeler-Kingshott CAM. Frontal and Cerebellar Atrophy Supports FTSD-ALS Clinical Continuum. *Front Aging Neurosci*. 2020 Nov 26;12:593526. doi: 10.3389/fnagi.2020.593526. PMID: 33324193; PMCID: PMC7726473. Impact Factor 3.2

Todisco M, Picascia M, Pisano P, Zangaglia R, Minafra B, **Vitali P**, Rognone E, Pichiecchio A, Ceravolo R, Vanacore N, Fasano A, Pacchetti C. Lumboperitoneal shunt in idiopathic normal pressure hydrocephalus: a prospective controlled study. *J Neurol*. 2020 Sep;267(9):2556-2566. doi: 10.1007/s00415-020-09844-x. Epub 2020 May 5. PMID: 32372182. Impact Factor 3.7

Pozzi NG, Brumberg J, Todisco M, Minafra B, Zangaglia R, Bossert I, Trifirò G, Ceravolo R, **Vitali P**, Isaias IU, Fasano A, Pacchetti C. Striatal Dopamine Deficit and Motor Impairment in Idiopathic Normal Pressure Hydrocephalus. *Mov Disord*. 2021 Jan;36(1):124-132. doi: 10.1002/mds.28366. Epub 2020 Nov 5. PMID: 33151012. Impact Factor 8.6

Vitali P, Pan MI, Palesi F, Germani G, Faggioli A, Anzalone N, Francaviglia P, Minafra B, Zangaglia R, Pacchetti C, Gandini Wheeler-Kingshott CAM. Substantia Nigra Volumetry with 3-T MRI in De Novo and Advanced Parkinson Disease. *Radiology*. 2020 Aug;296(2):401-410. doi: 10.1148/radiol.2020191235. Epub 2020 Jun 16. PMID: 32544035. Impact Factor 7.9

Melazzini L, **Vitali P**, Olivieri E, Bolchini M, Zanardo M, Savoldi F, Di Leo G, Griffanti L, Baselli G, Sardanelli F, Codari M. White Matter Hyperintensities Quantification in Healthy Adults: A Systematic Review and Meta-Analysis. *J Magn Reson Imaging*. 2020 Dec 20. doi: 10.1002/jmri.27479. Epub ahead of print. PMID: 33345393. Impact Factor 2.0

Castellazzi G, Cuzzoni MG, Cotta Ramusino M, Martinelli D, Denaro F, Ricciardi A, **Vitali P**, Anzalone N, Bernini S, Palesi F, Sinforiani E, Costa A, Micieli G, D'Angelo E, Magenes G, Gandini Wheeler-Kingshott CAM. A Machine Learning Approach for the Differential Diagnosis of Alzheimer and Vascular Dementia Fed by MRI Selected Features. *Front Neuroinform*. 2020 Jun 11;14:25. doi: 10.3389/fninf.2020.00025. PMID: 32595465; PMCID: PMC7300291. ****

Bouvier L, Monetta L, Laforce RJ, **Vitali P**, Bocti C, Martel-Sauvageau V. Progressive apraxia of speech in Quebec French speakers: A case series. *Int J Lang Commun Disord*. 2021 Feb 11. doi: 10.1111/1460-6984.12606. Epub ahead of print. PMID: 33570823. ***

Ismail Z, Black SE, Camicioli R, **Chertkow H**, Herrmann N, Laforce R Jr, Montero-Odasso M, Rockwood K, **Rosa-Neto P**, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, **Gauthier S**; CCCDTD5 participants. Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. *Alzheimers Dement*. 2020 Aug;16(8):1182-1195. doi: 10.1002/alz.12105. Epub 2020 Jul 29. PMID: 32725777. Impact Factor 17.1

Sheynin Y, **Rosa-Neto P**, Hess RF, Vaucher E. Cholinergic Modulation of Binocular Vision. *J Neurosci*. 2020 Jul 1;40(27):5208-5213. doi: 10.1523/JNEUROSCI.2484-19.2020. Epub 2020 May 26. PMID: 32457075; PMCID: PMC7329301. Impact Factor 5.6

Zukotynski K, Gaudet V, Uribe CF, Mathotaarachchi S, Smith KC, **Rosa-Neto P**, Bénard F, Black SE. Machine Learning in Nuclear Medicine: Part 2-Neural Networks and Clinical Aspects. *J Nucl Med*. 2021 Jan;62(1):22-29. doi: 10.2967/jnumed.119.231837. Epub 2020 Sep 25. PMID: 32978286. Impact Factor 7.3

Benedet AL, Leuzy A, Pascoal TA, Ashton NJ, Mathotaarachchi S, Savard M, Therriault J, Kang MS, Chamoun M, Schöll M, **Zimmer ER, Gauthier S**, Labbe A, Zetterberg H, **Rosa-Neto P**, Blennow K; Alzheimer's Disease Neuroimaging Initiative. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. *Brain*. 2020 Dec 1;143(12):3793-3804. doi: 10.1093/brain/awaa342. PMID: 33210117; PMCID: PMC7805809 Impact Factor 11.3

Knudsen GM, Ganz M, Appelhoff S, Boellaard R, Bormans G, Carson RE, Catana C, Doudet D, Gee AD, Greve DN, Gunn RN, Halldin C, Herscovitch P, Huang H, Keller SH, Lammertsma AA, Lanzenberger R, Liow JS, Lohith TG, Lubberink M, Lyoo CH, Mann JJ, Matheson GJ, Nichols TE, Nørgaard M, Ogden T, Parsey R, Pike VW, Price J, Rizzo G, **Rosa-Neto P**, Schain M, Scott PJ, Searle G, Slifstein M, Suhara T, Talbot PS, Thomas A, Veronese M, Wong DF, Yaqub M, Zanderigo F, Zoghbi S, Innis RB. Guidelines for the content and format of PET brain data in publications and archives: A consensus paper. *J Cereb Blood Flow Metab*. 2020 Aug;40(8):1576-1585. doi: 10.1177/0271678X20905433. Epub 2020 Feb 16. PMID: 32065076; PMCID: PMC7370374. Impact Factor 6.0

Singleton TA, Bdair H, Bailey JJ, Choi S, Aliaga A, **Rosa-Neto P**, Schirmacher R, Bernard-Gauthier V, Kostikov A. Efficient radiosynthesis and preclinical evaluation of [18 F]FOMPyD as a positron emission tomography tracer candidate for TrkB/C receptor imaging. *J Labelled Comp Radiopharm*. 2020 Mar;63(3):144-150. doi: 10.1002/jlcr.3827. Epub 2020 Jan 29. PMID: 31919878. Impact Factor 1.2

Dehghani M, Zhang S, Kumaragamage C, **Rosa-Neto P**, Near J. Dynamic 1 H-MRS for detection of 13 C-labeled glucose metabolism in the human brain at 3T. *Magn Reson Med*. 2020 Sep;84(3):1140-1151. doi: 10.1002/mrm.28188. Epub 2020 Jan 31. PMID: 32003052. Impact Factor 3.6

Paquin V, Therriault J, Pascoal TA, **Rosa-Neto P, Gauthier S**. Frontal Variant of Alzheimer Disease Differentiated From Frontotemporal Dementia Using in Vivo Amyloid and Tau Imaging. *Cogn Behav Neurol*. 2020 Dec;33(4):288-293. doi: 10.1097/WNN.0000000000000251. PMID: 33264158. Impact Factor 3.6

Ng KP, Pascoal TA, Mathotaarachchi S, Chan YH, Jiang L, Therriault J, Benedet AL, Shin M, Kandiah N, Greenwood CMT, **Rosa-Neto P, Gauthier S**; Dominantly Inherited Alzheimer Network. Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease. *Transl Neurodegener*. 2021 Jan 4;10(1):1. doi: 10.1186/s40035-020-00225-y. PMID: 33390174; PMCID: PMC7780680. ****

Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, Snellman A, Schöll M, Troakes C, Hye A, **Gauthier S**, Vanmechelen E, Zetterberg H, **Rosa-Neto P**, Blennow K. Plasma p-tau₂₃₁: a new biomarker for incipient Alzheimer's disease pathology. *Acta Neuropathol*. 2021 Feb 14. doi: 10.1007/s00401-021-02275-6. Epub ahead of print. PMID: 33585983. Impact Factor 18.1

Simrén J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, Mattsson-Carlsson N, Schöll M, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, Lovestone S, Aarsland D; AddNeuroMed consortium, Hansson O, **Rosa-Neto P**, Westman E, Blennow K, Zetterberg H, Ashton NJ. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. *Alzheimers Dement*. 2021 Jan 25. doi: 10.1002/alz.12283. Epub ahead of print. PMID: 33491853. Impact Factor 17.1